Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 1
1989 1
1990 1
1992 1
1993 7
1994 1
1995 5
1996 2
1997 5
1998 2
1999 4
2000 7
2001 9
2002 5
2003 4
2004 11
2005 12
2006 8
2007 11
2008 12
2009 8
2010 7
2011 4
2012 7
2013 15
2014 12
2015 11
2016 8
2017 7
2018 10
2019 11
2020 16
2021 18
2022 12
2023 13
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Among authors: carbone v. Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3. Ann Oncol. 2024. PMID: 38704093 Clinical Trial.
PediaVirus chatline: all together against COVID-19.
Iafusco M, Ciampa C, De Maddi F, Palamone G, Quarantiello F, De Luca G, Iannello C, Pisano S, Nocerino A, Russo R, Orlando F, Iafusco D; PediaVirus Network. Iafusco M, et al. Arch Dis Child. 2021 Mar;106(3):e12. doi: 10.1136/archdischild-2020-319551. Epub 2020 Jul 20. Arch Dis Child. 2021. PMID: 32690580 No abstract available.
Management of STEC Gastroenteritis: Is There a Role for Probiotics?
Giordano M, Baldassarre ME, Palmieri V, Torres DD, Carbone V, Santangelo L, Gentile F, Panza R, Di Mauro F, Capozza M, Di Mauro A, Laforgia N. Giordano M, et al. Among authors: carbone v. Int J Environ Res Public Health. 2019 May 12;16(9):1649. doi: 10.3390/ijerph16091649. Int J Environ Res Public Health. 2019. PMID: 31083597 Free PMC article. Review.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A, Carbone V, Pignata S, Mazzeo R, Lorusso D, Scambia G, Canova S, Di Palma T, Tasca G, Mantiero M, Naglieri E, Andreetta C, Rauso M, Brunetti AE, Laera L, Abeni C, Scandurra G, Gambaro AR, Pastore A, Bengala C, Gunnellini M, Farolfi A, Spinello M, Bartoletti M. Passarelli A, et al. Among authors: carbone v. Gynecol Oncol. 2024 Apr;183:61-67. doi: 10.1016/j.ygyno.2024.02.029. Epub 2024 Mar 21. Gynecol Oncol. 2024. PMID: 38518529 Free article.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: carbone v. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
A Tribute to the Life of Jack Michael.
Carbone VJ. Carbone VJ. Anal Verbal Behav. 2021 May 7;37(1):167-169. doi: 10.1007/s40616-021-00148-3. eCollection 2021 Jun. Anal Verbal Behav. 2021. PMID: 34395175 Free PMC article. No abstract available.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Among authors: carbone v. Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30. Eur J Cancer. 2024. PMID: 38598922
261 results